abacavir-lamivudine
PrintTrade Name(s): Abacavir-Lamivudine; Epzicom | |
Group 2: Non-Antineoplastic Hazardous | AHFS Class: HIV Nucleoside and Nucleotide Reverse Transcriptase Inhibitors |
Formweb: abacavir-lamivudine | |
Info Links: Chemotherapy Extravasation Policy |
Abacavir: Abacavir is a carbocyclic synthetic nucleoside analogue and an antiviral agent. Intracellularly, abacavir is converted by cellular enzymes to the active metabolite carbovir triphosphate, an analogue of deoxyguanosine-5'-triphosphate (dGTP). Carbovir triphosphate inhibits the activity of HIV-1 reverse transcriptase (RT) both by competing with the natural substrate dGTP and by its incorporation into viral DNA. Viral DNA growth is terminated because the incorporated nucleotide lacks a 3'-OH group, which is needed to form the 5′ to 3′ phosphodiester linkage essential for DNA chain elongation.
Reference: Drug Bank
Lamivudine: Lamivudine is a synthetic nucleoside analogue and is phosphorylated intracellularly to its active 5'-triphosphate metabolite, lamivudine triphosphate (L-TP). This nucleoside analogue is incorporated into viral DNA by HIV reverse transcriptase and HBV polymerase, resulting in DNA chain termination.
Reference: Drug Bank
abacavir:
- Suspected of causing genetic defects.
- Suspected of causing cancer.
- Suspected of damaging fertility or the unborn child.
- Causes serious eye irritation.
- May cause an allergic skin reaction.
Reference: SDS - Cayman Chemical
lamivudine:
- Suspected of damaging fertility or the unborn child.
Reference: SDS - Cayman Chemical